Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder

Journal of Clinical Psychopharmacology

Volumn 23, Issue 5, 2003, Pages 451-458

  De Berardis, Domenico ^a   Campanella, Daniela ^a   Matera, Vincenzo ^a   Gambi, Francesco ^a   La Rovere, Raffaella ^a   Sepede, Gianna ^a   Grimaldi, Maria Rosaria ^a   Pacilli, Anna Maria ^a   Salerno, Rosa Maria ^a   Ferro, Filippo Maria ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VALPROIC ACID;

ADULT; ARTICLE; BIPOLAR DISORDER; BLEEDING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE RELEASE REACTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; NORMAL DISTRIBUTION; PLATELET COUNT; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THROMBOCYTOPENIA; VALPROIC ACID;

EID: 10744225030     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000088911.24613.0d     Document Type: Article

References (50)

1. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Postgrad Med. 2000;76(Apr, special issue):1-104.
2. McElroy SL, Keck PE Jr. Treatment guidelines for valproate in bipolar and schizoaffective disorder. Can J Psychiatry. 1993;38:S62-S66.
3. Schaff MR, Fawcett J, Zajecka JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993;54:380-384.
4. Calabrese JR. Rapid cycling bipolar disorder and its treatment with valproate. Can J Psychiatry. 1993;38:S57-S61.
5. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs. lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271:918-924.
6. Calabrese JR, Woyshvie MJ. A medication algorithm for treatment of bipolar cycling? J Clin Psychiatry. 1995;56(suppl 3):11-18.
7. Balfour JA, Bryson HM. Valproic acid. A review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs. 1994;2:144-173.
8. Emilien G, Maloteaux JM, Seghers A, et al. Lithium compared to valproic acid and carbamazepine in the treatment of mania: a statistical meta-analysis. Eur Neuropsychopharmacol. 1996;6:245-252.
9. Walden J, Normann C, Langosch J, et al. Differential treatment of bipolar disorder with old and new antiepileptic drugs. Neuropsychobiology. 1998;38:181-184.
10. Lennkh C, Simhandi C. Current aspects of valproate in bipolar disorder. Int Clin Psychopharmacol. 2000;15:1-11.
11. Bowden CL. Predictors of response to divalproex and lithium. J Clin Psychiatry. 1995;56(suppl 3):25-30.
12. Abbott Laboratories. Depakote (divalproex sodium) product information. Chicago, IL: Abbot Laboratories; 2000.
13. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379-385.
14. May RB, Sunder TR. Hematological manifestations of long-term valproate therapy. Epilepsia. 1993;34:1098-1101.
15. Holland KD. Efficacy, pharmacology and adverse effects of antiepileptic drugs. Neurol Clin. 2001;19:313-345.
16. Smith FR, Boots M. Sodium valproate and bone marrow suppression. Ann Neurol. 1980;8:197-199.
17. Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Epilepsia. 1991;32(suppl 5):74S-79S.
18. Ishikita T, Ishiguro A, Fujisawa K, et al. Carbamazepine-induced thrombocytopenia defined by a challenge test. Am J Hematol. 1999;62:52-55.
19. Kimura M, Yoshino K, Maeoka J, et al. Carbamazepine-induced thrombocytopenia and carbamazepine-10,11-epoxide. A case report. Psychiatry Clin Neurosci. 1995;49:69-70.
20. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol. 1984;17:665-669.
21. Gidal B, Spencer N, Maly M, et al. Valproate-mediated disturbances of hemostasis: relationship to dose and plasma concentration. Neurology. 1994;44:1418-1422.
22. Tohen M, Castillo J, Baldessarini RJ, et al. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995;152:413-418.
23. Trannel TJ, Ahmed I, Doebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry. 2001;158:128-130.
24. Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol. 1979;5:389-390.
25. Morris N, Barr RD, Pai KR, et al. Valproic acid and thrombocytopenia. Can Med Assoc J. 1981;125:63-64.
26. Raworth RE, Birchall G. Sodium valproate and platelet count. Lancet. 1978;1:670-671.
27. Conley EL, Coley KC, Pollock BG, et al. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy. 2001;21:1325-1330.
28. Fawcett RG. Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder [letter]. J Clin Psychiatry. 1997;58:125.
29. Kaufman KR, Gerner R. Dose-dependent valproic acid thrombocytopenia in bipolar disorder. Ann Clin Psychiatry. 1998;10:35-37.
30. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug specific characteristics of thrombocytopenia caused by noncytotoxic drugs. Eur J Clin Pharmacol. 1998;54:9-10.
31. Delgado MR, Riela AR, Mills J, et al. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol. 1994;9:311-314.
32. Watts RG, Emanuel PD, Zuckerman KS, et al. Valproic acid induced cytopenias: evidence for a dose-related suppression of hematopoiesis. J Pediatr. 1990;117:495-499.
33. Barr RD, Copeland SA, Stockwell ML, et al. Valproic acid and immune thrombocytopenia. Arch Dis Child. 1982;57:681-684.
34. Rochel M, Ehrental W. Hematological side effects of valproic acid. In: Oxley J, Janz D, Meinardi H, eds. Antiepileptic Therapy: Chronic Toxicity of Antiepileptic Drugs. New York: Raven Press; 1993:101-103.
35. Wilder BJ, Rangel RJ. Clinically relevant antiepileptic drug interactions. In: Pitlick WH, ed. Antiepileptic Drug Interactions. New York: Demos; 1989:65-74.
36. Finsterer J, Pelzl G, Hess B. Severe, isolated thrombocytopenia under polytherapy with carbamazepine and valproate. Psychiatry Clin Neurosci. 2001 Aug;55(4):423-426.
37. Hoffman LM. Sodium valproate and thrombocytopenia. Can Med Assoc J. 1982;126:358-359.
38. Vasudev K, Groswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl). 2000;150:15-23.
39. Kis B, Szupera Z, Mezei Z, et al. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia. 1999 Mar; 40(3):307-310.
40. Szupera Z, Mezei Z, Kis B, et al. The effects of valproate on the arachidonic acid metabolism of rat brain microvessels and of platelets. Eur J Pharmacol. 2000 Jan 10;387(2):205-210.
41. Richardson SGN, Fletcher DJ, Jeavson PM, et al. Sodium valproate and platelet function. BMJ. 1976;1:221-222.
42. Von Voss H, Petrich C, Karch D, et al. Sodium valproate and platelet function [letter]. BMJ. 1976;2:179.
43. Winfield DA, Benton P, Espri MLE, et al. Sodium valproate and thrombocytopenia. BMJ. 1976;2:981.
44. Anderson GD, Lin YX, Berge C, et al. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg. 1997 Aug;87(2):252-256.
45. Kishi T, Fujita N, Kawaguchi H, et al. Bone marrow suppression induced by high dose valproic acid. Arch Dis Child. 1994;71:153-155.
46. Iinuma K, Hayasaka K, Narisawa K, et al. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid. Eur J Pediatr. 1988 Dec; 148(3):267-269.
47. Von Voss HV, Schlte-Berbuhl R, Gobel U. Side effects of sodium valproate (sodium di-n-propylacetate) on malonydialdehyde production and other platelet function tests. Minerva Pediatr. 1978;30:1397-1404.
48. Chong BH. Drug-induced immune thrombocytopenia. Platelets. 1991;2:173.
49. Rizvi MA, Shah SR, Raskob GE, et al. Drug-induced thrombocytopenia. Curr Opin Hematol. 1999;6(5):349-353.
50. Sandler RM, Emberson C, Roberts GE, et al. IgM platelet autoantibody due to sodium valproate. BMJ. 1978 Dec;2(6153):1683-1684.